Drug Profile

WTX 330

Alternative Names: WTX-330

Latest Information Update: 29 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Werewolf Therapeutics
Class Antineoplastics; Immunotherapies; Interleukins
Mechanism of Action Interleukin 12 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

18 Dec 2025 WTX 330 is available for licensing as of 18 Dec 2025. https://werewolftx.com/
18 Dec 2025 Efficacy, adverse events and pharmacokinetics data from a phase Ib/II trial in Solid tumours released by Werewolf Therapeutics
30 Apr 2025 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06939283)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com